Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Precision Medicine and Therapeutic Resistance
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Precision Medicine and Therapeutic Resistance
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

MYB–QKI Fusions Drive Angiocentric Glioma through Multiple Mechanisms

DOI: 10.1158/2159-8290.CD-RW2016-025 Published March 2016
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading
  • Major finding: MYB–QKI rearrangement promotes angiocentric glioma via three genetic and epigenetic mechanisms.

  • Mechanism: MYB–QKI promotes glioma tumorigenesis via MYB truncation, enhancer translocation, and QKI loss.

  • Impact: MYB–QKI rearrangements are unique to angiocentric glioma and may serve as diagnostic markers.

Figure1

Pediatric low-grade gliomas (PLGG) are a heterogeneous group of tumors, including angiocentric glioma, that often harbor MYB alterations. However, the specific alterations and their functions have not been determined in angiocentric glioma. In order to identify recurrent alterations, Bandopadhayay and colleagues analyzed whole-genome and RNA-sequencing data from 172 PLGGs, including seven angiocentric gliomas. All seven angiocentric gliomas harbored MYB translocations, including 6 MYB–QKI fusions and 1 MYB–ESR1 fusion. The MYB–QKI fusion was specific to angiocentric gliomas, and not detected in any of the tested nonangiocentric gliomas. The translocation resulted in an in-frame fusion of the MYB DNA-binding domain to the C-terminus of QKI, which encodes the RNA-binding protein Quaking. Gene expression analysis in mouse neural stem cells (mNSC) stably expressing MYB–QKI indicated that MYB pathway genes were activated by MYB–QKI. Furthermore, chromatin immunoprecipitation sequencing revealed that MYB–QKI predominantly bound to the MYB binding motif in enhancer regions marked by acetylation of histone H3 at lysine 27, and MYB–QKI functioned as a transcription factor that activated the MYB promoter more strongly than MYB. In normal cortical brain, the 3′ end of QKI is associated with active enhancers while the MYB locus is not, but the MYB–QKI rearrangement brought the QKI enhancers in proximity to the MYB promoter, enhancing aberrant expression of activated truncated MYB. The MYB–QKI fusion was oncogenic, as its stable expression in mNSCs promoted proliferation and tumor formation in vivo. In addition, wild-type QKI is a tumor suppressor, and suppressing the first 4 exons of QKI, as occurs with the MYB–QKI translocation, increased proliferation. Together, these findings suggest that MYB-QKI is a specific oncogenic driver in angiocentric gliomas and promotes tumor growth through the oncogenic function of the MYB–QKI fusion transcription factor, activation of the MYB promoter via translocation of the QKI enhancer, and loss of QKI tumor suppressor function.

Bandopadhayay P, Ramkissoon LA, Jain P, Bergthold G, Wala J, Zeid R, et al. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet 2016 Feb 1 [Epub ahead of print].

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2016 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 6 (3)
March 2016
Volume 6, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
MYB–QKI Fusions Drive Angiocentric Glioma through Multiple Mechanisms
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
MYB–QKI Fusions Drive Angiocentric Glioma through Multiple Mechanisms
Cancer Discov March 1 2016 (6) (3) 228; DOI: 10.1158/2159-8290.CD-RW2016-025

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
MYB–QKI Fusions Drive Angiocentric Glioma through Multiple Mechanisms
Cancer Discov March 1 2016 (6) (3) 228; DOI: 10.1158/2159-8290.CD-RW2016-025
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Cell-Intrinsic Programs Partition Nutrients in Tumor Microenvironment
  • Extrachromosomal DNA Can Promote Oncogene Transcription in Trans
  • Transient Rest Reverses Exhaustion of Chimeric Antigen Receptor T Cells
Show more Research Watch

Glioma

  • Distinct Transitional States of Glial Progenitors Drive Gliomagenesis
  • Unique Molecular Landscapes Distinguish Low- and High-Grade NF1 Gliomas
  • (R)-2HG Inhibits the BCAT Transaminase in IDH-Mutant Glioma
Show more Glioma
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement